IL323224A - Crystalline form - Google Patents

Crystalline form

Info

Publication number
IL323224A
IL323224A IL323224A IL32322425A IL323224A IL 323224 A IL323224 A IL 323224A IL 323224 A IL323224 A IL 323224A IL 32322425 A IL32322425 A IL 32322425A IL 323224 A IL323224 A IL 323224A
Authority
IL
Israel
Prior art keywords
compound
crystalline form
fluoro
mmol
ray powder
Prior art date
Application number
IL323224A
Other languages
English (en)
Hebrew (he)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL323224A publication Critical patent/IL323224A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL323224A 2023-03-13 2025-09-08 Crystalline form IL323224A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23161547 2023-03-13
PCT/EP2024/056495 WO2024188999A1 (en) 2023-03-13 2024-03-12 Crystalline form

Publications (1)

Publication Number Publication Date
IL323224A true IL323224A (en) 2025-11-01

Family

ID=85601718

Family Applications (1)

Application Number Title Priority Date Filing Date
IL323224A IL323224A (en) 2023-03-13 2025-09-08 Crystalline form

Country Status (9)

Country Link
EP (1) EP4680340A1 (es)
JP (1) JP2026508943A (es)
KR (1) KR20250155619A (es)
CN (1) CN120917029A (es)
AU (1) AU2024236796A1 (es)
CL (1) CL2025002744A1 (es)
IL (1) IL323224A (es)
MX (1) MX2025010674A (es)
WO (1) WO2024188999A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20260121A1 (es) 2023-04-21 2026-01-16 Gilead Sciences Inc Inhibidores de prmt5 y usos de los mismos
WO2026114356A1 (zh) * 2024-11-29 2026-06-04 普罗思特(南京)生物科技有限公司 含氮杂环化合物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4304720A1 (en) * 2021-03-11 2024-01-17 Mirati Therapeutics, Inc. Mta-cooperative prmt5 inhibitors
US20240368153A1 (en) * 2021-07-02 2024-11-07 Mirati Therapeutics, Inc. Aminopyridine-based MTA-Cooperative PRMT5 Inhibitors
EP4402143A1 (en) 2021-09-13 2024-07-24 Astrazeneca AB Spirocyclic compounds

Also Published As

Publication number Publication date
CL2025002744A1 (es) 2026-01-02
KR20250155619A (ko) 2025-10-30
MX2025010674A (es) 2025-10-01
AU2024236796A1 (en) 2025-10-30
WO2024188999A1 (en) 2024-09-19
JP2026508943A (ja) 2026-03-13
EP4680340A1 (en) 2026-01-21
CN120917029A (zh) 2025-11-07

Similar Documents

Publication Publication Date Title
CN104411700B (zh) 4-[5-(吡啶-4-基)-1h-1,2,4-三唑-3-基]吡啶-2-腈的多晶型及其制造方法
JP7406674B2 (ja) スピロ環化合物
WO2024188999A1 (en) Crystalline form
EP3183253B1 (en) Salt of (r)-3-(4-(7h-pyrrolo [2,3-d]pyrimidin-4-yl)-lh-pyrazol-l-yl)-3-cyclopentylpropanenitrile with benzenesulfonic acid
CN110678178A (zh) Mk2抑制剂的形式和组合物
JP2025538506A (ja) がんの治療のための縮合ピリジンの固体形態
TW202233607A (zh) Kras g12c抑制劑化合物之新結晶形式
CN120882710A (zh) 氮杂环丁烷parp1抑制剂的结晶形式
CN114075199A (zh) Jak抑制剂化合物及其用途
WO2014159353A1 (en) Solid state forms of vemurafenib hydrochloride
JP7068402B2 (ja) チアゾール誘導体の製造方法
CN114401720A (zh) 多酪氨酸激酶抑制剂的晶型、制备方法及其用途
EP4293021A1 (en) Salt of nitrogen-containing fused heterocyclic compound or crystal form thereof, and preparation method therefor, pharmaceutical composition thereof, and use thereof
CN111484488A (zh) 一种b-raf激酶二聚体抑制剂的稳定结晶形式a
KR102858471B1 (ko) Lta4h 저해제의 결정질 형태
JP2024520920A (ja) イミダゾリジノン類化合物の多形体、調製方法及びその使用
CA2596754C (en) Crystalline 1h-imidazo[4,5-b]pyridin-5-amine,7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its uses for the treatment of inflammatory, autoimmune and proliferative diseases and disorders
EP4467536A1 (en) Crystalline form of sulfur-containing isoindoline derivative
EP4714947A1 (en) Crystal form of pyrimido azacyclo compound, and preparation method therefor and use thereof
CN109516976B (zh) 取代嘧啶类pi3k抑制剂甲磺酸盐的晶型及其制备方法
KR20260069720A (ko) 트리아졸로피리미디논 유도체의 결정형
HK40061484A (en) Jak inhibitor compound and use thereof
TW202606690A (zh) 吡啶并吡唑衍生物的晶型物、藥物組合物及其用途
WO2025229146A1 (en) Crystalline form of a pyridazine nlrp3 inhibitor
CA3246483A1 (en) Crystal form of a fused ring derivative, a prepartion method therefor and use thereof